🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "huge turning point" in the fight against increasingly resistant strains of the bacteria, according to researchers.

An International Health Concern

The sexually transmitted infection are escalating around the world, with estimates suggesting more than 82 million new cases annually. Particularly high rates are seen in Africa and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Medical experts are increasingly worried about the surge in antibiotic-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Therapies Receive Approval

Zoliflodacin, also known as a brand name, was cleared by the American regulatory agency in December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers anticipate that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This drug, which is employed against UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This approval marks a major breakthrough in the management of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Testing Results and Global Access

Based on results released by a major medical journal, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which uses an injection and a pill. The trial enrolled hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the rights to make available and distribute the drug in many developing nations.

Medical professionals treating patients have expressed optimism. Having a easy-to-administer therapy like this is described as a "revolutionary step" for managing the epidemic. This is considered crucial to lessen the impact of the infection for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.